BioMarin Pharmaceutical Inc. (0HNC.L)
USD 60.0
(2.51%)
USD 60.0
(2.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.74 Billion USD | 7.24% |
| 2022 | 1.57 Billion USD | 7.73% |
| 2021 | 1.45 Billion USD | 1.79% |
| 2020 | 1.43 Billion USD | -2.56% |
| 2019 | 1.47 Billion USD | 8.93% |
| 2018 | 1.34 Billion USD | 11.38% |
| 2017 | 1.21 Billion USD | 9.0% |
| 2016 | 1.11 Billion USD | 9.04% |
| 2015 | 1.01 Billion USD | 30.41% |
| 2014 | 781.66 Million USD | 28.41% |
| 2013 | 608.75 Million USD | 17.27% |
| 2012 | 519.1 Million USD | 33.17% |
| 2011 | 389.79 Million USD | 30.35% |
| 2010 | 299.03 Million USD | 23.4% |
| 2009 | 242.32 Million USD | 18.65% |
| 2008 | 204.22 Million USD | 27.24% |
| 2007 | 160.51 Million USD | 60.28% |
| 2006 | 100.14 Million USD | 14.77% |
| 2005 | 87.25 Million USD | -46.34% |
| 2004 | 162.6 Million USD | 84.98% |
| 2003 | 87.9 Million USD | 7.8% |
| 2002 | 81.54 Million USD | 56.81% |
| 2001 | 52 Million USD | 0.12% |
| 2000 | 51.94 Million USD | 28.03% |
| 1999 | 40.56 Million USD | 174.11% |
| 1998 | 14.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 460.44 Million USD | 7.71% |
| 2024 Q1 | 427.49 Million USD | -13.9% |
| 2024 Q3 | 443.39 Billion USD | -3.7% |
| 2023 Q4 | 496.51 Million USD | 17.46% |
| 2023 FY | 1.68 Billion USD | 7.24% |
| 2023 Q2 | 394.14 Million USD | 1.0% |
| 2023 Q3 | 422.7 Million USD | 7.25% |
| 2023 Q1 | 390.23 Million USD | -10.24% |
| 2022 FY | 1.57 Billion USD | 7.73% |
| 2022 Q1 | 373.06 Million USD | -5.78% |
| 2022 Q2 | 371.52 Million USD | -0.41% |
| 2022 Q4 | 434.74 Million USD | 11.05% |
| 2022 Q3 | 391.47 Million USD | 5.37% |
| 2021 FY | 1.45 Billion USD | 1.79% |
| 2021 Q3 | 358.42 Million USD | -1.25% |
| 2021 Q2 | 362.95 Million USD | 6.51% |
| 2021 Q1 | 340.77 Million USD | -8.1% |
| 2021 Q4 | 395.94 Million USD | 10.47% |
| 2020 Q1 | 345.22 Million USD | -8.6% |
| 2020 FY | 1.43 Billion USD | -2.56% |
| 2020 Q2 | 372.46 Million USD | 7.89% |
| 2020 Q3 | 343.93 Million USD | -7.66% |
| 2020 Q4 | 370.81 Million USD | 7.82% |
| 2019 Q4 | 377.7 Million USD | 4.88% |
| 2019 Q1 | 365.51 Million USD | 5.54% |
| 2019 Q2 | 366.68 Million USD | 0.32% |
| 2019 FY | 1.47 Billion USD | 8.93% |
| 2019 Q3 | 360.13 Million USD | -1.78% |
| 2018 Q4 | 346.34 Million USD | 5.41% |
| 2018 Q3 | 328.55 Million USD | -3.11% |
| 2018 Q2 | 339.08 Million USD | 1.07% |
| 2018 Q1 | 335.48 Million USD | -3.94% |
| 2018 FY | 1.34 Billion USD | 11.38% |
| 2017 Q4 | 349.26 Million USD | 21.11% |
| 2017 Q2 | 299.95 Million USD | 9.49% |
| 2017 Q3 | 288.39 Million USD | -3.85% |
| 2017 Q1 | 273.94 Million USD | -15.85% |
| 2017 FY | 1.21 Billion USD | 9.0% |
| 2016 Q3 | 289.24 Million USD | 30.17% |
| 2016 Q4 | 325.56 Million USD | 12.56% |
| 2016 Q2 | 222.2 Million USD | -19.06% |
| 2016 Q1 | 274.53 Million USD | 10.09% |
| 2016 FY | 1.11 Billion USD | 9.04% |
| 2015 Q1 | 236.31 Million USD | -3.07% |
| 2015 Q4 | 249.37 Million USD | -1.84% |
| 2015 FY | 1.01 Billion USD | 30.41% |
| 2015 Q3 | 254.05 Million USD | -7.58% |
| 2015 Q2 | 274.88 Million USD | 16.32% |
| 2014 Q2 | 179.45 Million USD | 15.64% |
| 2014 Q4 | 243.79 Million USD | 19.96% |
| 2014 FY | 781.66 Million USD | 28.41% |
| 2014 Q1 | 155.19 Million USD | -11.1% |
| 2014 Q3 | 203.22 Million USD | 13.24% |
| 2013 Q1 | 140.34 Million USD | -7.85% |
| 2013 Q4 | 174.56 Million USD | 9.41% |
| 2013 FY | 608.75 Million USD | 17.27% |
| 2013 Q3 | 159.54 Million USD | 18.8% |
| 2013 Q2 | 134.29 Million USD | -4.31% |
| 2012 Q1 | 119.08 Million USD | 10.48% |
| 2012 FY | 519.1 Million USD | 33.17% |
| 2012 Q4 | 152.31 Million USD | 35.33% |
| 2012 Q3 | 112.54 Million USD | -12.99% |
| 2012 Q2 | 129.35 Million USD | 8.62% |
| 2011 Q2 | 90.6 Million USD | 4.9% |
| 2011 Q1 | 86.36 Million USD | 2.21% |
| 2011 FY | 389.79 Million USD | 30.35% |
| 2011 Q4 | 107.79 Million USD | 4.19% |
| 2011 Q3 | 103.45 Million USD | 14.19% |
| 2010 FY | 299.03 Million USD | 23.4% |
| 2010 Q1 | 64.75 Million USD | 1.22% |
| 2010 Q2 | 74.5 Million USD | 15.07% |
| 2010 Q3 | 81.68 Million USD | 9.64% |
| 2010 Q4 | 84.49 Million USD | 3.44% |
| 2009 FY | 242.32 Million USD | 18.65% |
| 2009 Q4 | 63.97 Million USD | 14.84% |
| 2009 Q1 | 64.01 Million USD | 15.24% |
| 2009 Q2 | 58.62 Million USD | -8.42% |
| 2009 Q3 | 55.7 Million USD | -4.98% |
| 2008 Q2 | 50.05 Million USD | 18.07% |
| 2008 FY | 204.22 Million USD | 27.24% |
| 2008 Q1 | 42.39 Million USD | -13.49% |
| 2008 Q4 | 55.55 Million USD | -1.2% |
| 2008 Q3 | 56.23 Million USD | 12.35% |
| 2007 Q2 | 37.92 Million USD | 6.73% |
| 2007 Q1 | 35.53 Million USD | 18.59% |
| 2007 Q4 | 49 Million USD | 28.79% |
| 2007 FY | 160.51 Million USD | 60.28% |
| 2007 Q3 | 38.04 Million USD | 0.31% |
| 2006 Q4 | 29.96 Million USD | 13.37% |
| 2006 Q2 | 23.99 Million USD | 21.52% |
| 2006 Q1 | 19.74 Million USD | -5.84% |
| 2006 FY | 100.14 Million USD | 14.77% |
| 2006 Q3 | 26.43 Million USD | 10.14% |
| 2005 Q2 | 21.92 Million USD | -23.77% |
| 2005 FY | 87.25 Million USD | -46.34% |
| 2005 Q4 | 20.97 Million USD | 1.87% |
| 2005 Q3 | 20.58 Million USD | -6.08% |
| 2005 Q1 | 28.75 Million USD | -69.45% |
| 2004 FY | 162.6 Million USD | 84.98% |
| 2004 Q2 | 22.34 Million USD | 15.59% |
| 2004 Q3 | 26.76 Million USD | 19.77% |
| 2004 Q4 | 94.14 Million USD | 251.72% |
| 2004 Q1 | 19.33 Million USD | -23.01% |
| 2003 Q1 | 24.03 Million USD | -18.2% |
| 2003 FY | 87.9 Million USD | 7.8% |
| 2003 Q4 | 25.11 Million USD | 21.49% |
| 2003 Q3 | 20.67 Million USD | -4.2% |
| 2003 Q2 | 21.57 Million USD | -10.24% |
| 2002 Q1 | 17.14 Million USD | 35.48% |
| 2002 Q3 | 18.61 Million USD | 13.52% |
| 2002 FY | 81.54 Million USD | 56.81% |
| 2002 Q4 | 29.38 Million USD | 57.86% |
| 2002 Q2 | 16.39 Million USD | -4.35% |
| 2001 Q2 | 14.02 Million USD | -0.45% |
| 2001 Q4 | 12.65 Million USD | -3.67% |
| 2001 Q3 | 13.13 Million USD | -6.33% |
| 2001 Q1 | 14.08 Million USD | -5.94% |
| 2001 FY | 52 Million USD | 0.12% |
| 2000 Q2 | 11.8 Million USD | -4.75% |
| 2000 Q1 | 12.39 Million USD | -8.67% |
| 2000 Q3 | 12.76 Million USD | 8.16% |
| 2000 FY | 51.94 Million USD | 28.03% |
| 2000 Q4 | 14.97 Million USD | 17.31% |
| 1999 Q3 | 11.7 Million USD | 32.95% |
| 1999 Q2 | 8.8 Million USD | -62.39% |
| 1999 Q4 | 13.56 Million USD | 15.97% |
| 1999 FY | 40.56 Million USD | 174.11% |
| 1999 Q1 | 23.4 Million USD | 0.0% |
| 1998 FY | 14.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 82.97% |
| Dynavax Technologies Corporation | 219.14 Million USD | -696.858% |
| Illumina, Inc. | 3.81 Billion USD | 54.202% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 14.94% |
| Biogen Inc. | 5.2 Billion USD | 66.449% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -287.207% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -60.298% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -28.325% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -230.102% |
| Waters Corporation | 943.51 Million USD | -85.081% |
| Perrigo Company plc | 1.52 Billion USD | -14.248% |
| uniQure N.V. | 285.08 Million USD | -512.543% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -327.165% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -308.341% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -533.413% |
| bluebird bio, Inc. | 240.23 Million USD | -626.912% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1125.774% |
| Imunon, Inc. | 21.03 Million USD | -8203.563% |
| Myriad Genetics, Inc. | 600.1 Million USD | -190.997% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -9.381% |
| Nektar Therapeutics | 190.9 Million USD | -814.745% |
| Editas Medicine, Inc. | 247.3 Million USD | -606.125% |
| Verastem, Inc. | 92.08 Million USD | -1796.394% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 95.699% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -12454.422% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1347.305% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3809.542% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -663.633% |
| Evolus, Inc. | 189.75 Million USD | -820.259% |
| Adicet Bio, Inc. | 152.03 Million USD | -1048.578% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -14283.288% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 37.972% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -542.256% |
| FibroGen, Inc. | 398.11 Million USD | -338.638% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 17.434% |
| OPKO Health, Inc. | 574.68 Million USD | -203.866% |
| Homology Medicines, Inc. | 9.87 Million USD | -17583.797% |
| Geron Corporation | 70.44 Million USD | -2379.06% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 2.988% |
| Exelixis, Inc. | 1.58 Billion USD | -10.052% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1631.952% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -3031.995% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -216.603% |
| Zoetis Inc. | 2.76 Billion USD | 36.844% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -266.587% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -3500.419% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 63.429% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -4360.131% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -124.0% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -373.743% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -483.418% |
| Blueprint Medicines Corporation | 722.86 Million USD | -141.578% |
| Insmed Incorporated | 949.26 Million USD | -83.962% |
| TG Therapeutics, Inc. | 198.47 Million USD | -779.846% |
| Incyte Corporation | 1.19 Billion USD | -46.685% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -67.268% |